Drug Trial Radar · NCT04555525
A Pilot Study on the Use of Seysara for Rosacea
Last checked: Nov 20, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Apr 15, 2019
Primary completion
Sep 23, 2020
Study completion Oct 1, 2020
Sponsor
- Lead sponsor
- Derm Research, PLLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)
Conditions
- Acne Rosacea
Interventions
sarecyclineDrug
sarecycline tablet
Centrum Adult MultivitaminDietary supplement
Centrum Adult Mulltivitamin tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- IGA (Investigator Global Assessment)Time frame: 12 weeks
- Inflammatory Lesion CountTime frame: Baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Skin Sciences, PLLC
Louisville, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.